CompletedEarly Phase 1

RHD Genotype Matched Red Cells for Anti-D

United States5 participantsStarted 2020-07-08

Plain-language summary

This is a pilot study to evaluate the feasibility and safety of providing RH genotype matched D+ Red Blood Cells (RBCs) to chronically transfused patients with sickle cell disease (SCD) who type D+ but have formed anti-D and are currently transfused with D- RBC (Red Blood Cell) units.

Who can participate

Age range8 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects age \> 8 years old * Diagnosis of SCD, all genotypes * Require chronic red cell transfusion therapy * History of anti-D * RH genotype predicts D+ expression Exclusion Criteria: * Rare RH genotype that would preclude sufficient RBC units * Antigen negative requirements due to alloimmunization that would preclude sufficient RBC units

What they're measuring

Anti-D Recurrence

Timeframe: Through study completion and follow-up phase, an average of 10 months per participant

Trial details

NCT IDNCT04156906

SponsorChildren's Hospital of Philadelphia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-04

Results submitted2025-04-09

View on ClinicalTrials.gov More Sickle Cell Disease trials